pSivida is a global bio-nanotech company committed to the development of drug
delivery products in the healthcare sector, initially in ophthalmology and oncology.
pSivida is committed to the development of drug delivery products in the healthcare
sector, initially in ophthalmology and oncology. pSivida has developed the only
two FDA approved sustained release back of the eye treatments for chronic eye
disease, Vitrasert® and Retisert®. Both products are manufactured and
sold by global ophthalmology company, Bausch & Lomb.
A next generation product, Medidur™ is licensed for ophthalmic applications
to Pfizer Inc. Alimera Sciences has also licensed Medidur™ for the treatment
of Diabetic Macular Edema, the leading cause of vision loss for Americans under
the age of 65, which is presently in fully recruited Phase III clinical trials
that is following over 900 patients across the United States, Canada, Europe
and India. These trials are being fully funded by our development partner, Alimera
pSivida owns the right to develop and commercialize a new biomaterial, nanostructured
porous silicon (BioSilicon™), for multiple potential applications in healthcare
with a core focus on drug delivery. The lead BioSilicon™ product is BrachySil™,
a brachytherapy treatement in Phase II clinical trials, which is being developed
for the treatment of inoperable pancreatic cancer.
pSivida's largest shareholder and strategic partner is Pfizer (PFE). QinetiQ
(QQ.), the former United Kingdom Government Defence Evaluation & Research
Agency (DERA) and Europe's largest research and development organization is
a top five shareholder.
pSivida is listed on NASDAQ (PSDV), Australian (PVA), and Frankfurt (PSI) stock
exchanges and is a member of the NASDAQ Health Care Index (Nasdaq: IXHC) and
the Merrill Lynch Nanotechnology Index.